This Article Full Text Full Text (PDF) Publisher's Note Erratum (v26,p165) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heymach, J. V. Articles by Herbst, R. S. Search for Related Content PubMed Articles by Heymach, J. V. Articles by Herbst, R. S. Social Bookmarking                            What's this?

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

John V. Heymach, Bruce E. Johnson, Diane Prager, Edit Csada, Jaromír Roubec, Milo Peek, Irena pásová, Chandra P. Belani, István Bodrogi, Shirish Gadgeel, Sarah J. Kennedy, Jeannie Hou, Roy S. Herbst

From the Dana-Farber Cancer Institute, Boston, MA; UCLA Medical Center, Los Angeles, CA; University of Szeged, Szeged; National Institute of Oncology, Budapest, Hungary; University Hospital Ostrava-Poruba, Ostrava; University Hospital, Medical Faculty in Pilsen, Charles University, Prague, Czech Republic; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; Wayne State University/Karmanos Cancer Institute, Detroit, MI; AstraZeneca, Alderley Park, Macclesfield, United Kingdom; AstraZeneca, Wilmington, DE; and The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Roy S. Herbst, MD, PhD, Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030-4009; e-mail: rherbst{at}mdanderson.org

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity. The activity of vandetanib plus docetaxel was assessed in patients with previously treated non–small-cell lung cancer (NSCLC).

Patients and Methods This two-part study comprised an open-label run-in phase and a double-blind randomized phase. Eligible patients had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of first-line platinum-based chemotherapy. The primary objective of the randomized phase was to prolong progression-free survival (PFS) in patients receiving vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m² intravenous infusion every 21 days) versus placebo plus docetaxel. The study was designed to have more than 75% power to detect 50% prolongation at a one-sided significance level of P < .20. Secondary objectives included objective response rate, overall survival, safety and tolerability.

Results In the randomized phase (n = 127), median PFS was 18.7 weeks for vandetanib 100 mg plus docetaxel (n = 42; hazard ratio v docetaxel = 0.64; one-sided P = .037); 17.0 weeks for vandetanib 300 mg plus docetaxel (n = 44; hazard ratio v docetaxel = 0.83; one-sided P = .231); and 12 weeks for docetaxel (n = 41). There was no statistically significant difference in overall survival among the three treatment arms. Common adverse events included diarrhea, rash, and asymptomatic prolongation of corrected QT (QT_C) interval.

Conclusion The primary objective was achieved, with vandetanib 100 mg plus docetaxel demonstrating a significant prolongation of PFS compared with docetaxel in relation to the prespecified significance level. On the basis of these encouraging data, phase III evaluation of vandetanib 100 mg plus docetaxel in second-line NSCLC has been initiated.

Supported by AstraZeneca. J.V.H. is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04) and the American Society for Clinical Oncology Career Development Award.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA; 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; 11th World Conference on Lung Cancer, July 3-6, 2005, Barcelona, Spain; and the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.

ZACTIMA is a trademark of the AstraZeneca group of companies.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. M. Annunziata, A. J. Walker, L. Minasian, M. Yu, H. Kotz, B. J. Wood, K. Calvo, P. Choyke, D. Kimm, S. M. Steinberg, et al. Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 Clin. Cancer Res., January 15, 2010; 16(2): 664 - 672. [Abstract] [Full Text] [PDF]

				E. O. Hanrahan, H. Y. Lin, E. S. Kim, S. Yan, D. Z. Du, K. S. McKee, H. T. Tran, J. J. Lee, A. J. Ryan, P. Langmuir, et al. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., January 10, 2010; 28(2): 193 - 201. [Abstract] [Full Text] [PDF]

				G. Korpanty, E. Smyth, L. A Sullivan, R. A Brekken, and D. N Carney Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway Exp Biol Med, January 1, 2010; 235(1): 3 - 9. [Abstract] [Full Text] [PDF]

				M. L. Maitland, K. E. Kasza, T. Karrison, K. Moshier, L. Sit, H. R. Black, S. D. Undevia, W. M. Stadler, W. J. Elliott, and M. J. Ratain Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment Clin. Cancer Res., October 1, 2009; 15(19): 6250 - 6257. [Abstract] [Full Text] [PDF]

				M. P. Morelli, A. M. Brown, T. M. Pitts, J. J. Tentler, F. Ciardiello, A. Ryan, J. M. Jurgensmeier, and S. G. Eckhardt Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines Mol. Cancer Ther., September 1, 2009; 8(9): 2546 - 2558. [Abstract] [Full Text] [PDF]

				L. Horn and A. Sandler Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Clin. Cancer Res., August 15, 2009; 15(16): 5040 - 5048. [Abstract] [Full Text] [PDF]

				J. H. Schiller, T. Larson, S.-H. I. Ou, S. Limentani, A. Sandler, E. Vokes, S. Kim, K. Liau, P. Bycott, A. J. Olszanski, et al. Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study J. Clin. Oncol., August 10, 2009; 27(23): 3836 - 3841. [Abstract] [Full Text] [PDF]

				H. H. Kong, H. A. Fine, J. B. Stern, and M. L. C. Turner Cutaneous Pigmentation After Photosensitivity Induced by Vandetanib Therapy Arch Dermatol, August 1, 2009; 145(8): 923 - 925. [Abstract] [Full Text] [PDF]

				E. Ichihara, K. Ohashi, N. Takigawa, M. Osawa, A. Ogino, M. Tanimoto, and K. Kiura Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo Cancer Res., June 15, 2009; 69(12): 5091 - 5098. [Abstract] [Full Text] [PDF]

				E. O. Hanrahan, A. J. Ryan, H. Mann, S. J. Kennedy, P. Langmuir, R. B. Natale, R. S. Herbst, B. E. Johnson, and J. V. Heymach Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3600 - 3609. [Abstract] [Full Text] [PDF]

				G. N. Naumov, M. B. Nilsson, T. Cascone, A. Briggs, O. Straume, L. A. Akslen, E. Lifshits, L. A. Byers, L. Xu, H.-k. Wu, et al. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance Clin. Cancer Res., May 15, 2009; 15(10): 3484 - 3494. [Abstract] [Full Text] [PDF]

				N. Hawkins, D. A. Scott, and B. Woods How Far Do You Go? Efficient Searching for Indirect Evidence Med Decis Making, May 1, 2009; 29(3): 273 - 281. [Abstract] [PDF]

				L. Horn and A. B. Sandler Angiogenesis in the Treatment of Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 206 - 217. [Abstract] [Full Text] [PDF]

				A. Morabito, M. C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, J. Bryce, M. Di Maio, E. De Maio, N. Normanno, and F. Perrone Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions Oncologist, April 1, 2009; 14(4): 378 - 390. [Abstract] [Full Text] [PDF]

				N. A. Pennell and T. J. Lynch Jr. Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC Oncologist, April 1, 2009; 14(4): 399 - 411. [Abstract] [Full Text] [PDF]

				R. de Boer, Y. Humblet, J. Wolf, L. Nogova, K. Ruffert, T. Milenkova, R. Smith, A. Godwood, and J. Vansteenkiste An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer Ann. Onc., March 1, 2009; 20(3): 486 - 491. [Abstract] [Full Text] [PDF]

				J. V. Heymach, L. Paz-Ares, F. De Braud, M. Sebastian, D. J. Stewart, W. E.E. Eberhardt, A. A. Ranade, G. Cohen, J. M. Trigo, A. B. Sandler, et al. Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2008; 26(33): 5407 - 5415. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]

				E. L. Bradshaw-Pierce, C. A. Steinhauer, D. Raben, and D. L. Gustafson Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma Mol. Cancer Ther., September 1, 2008; 7(9): 3006 - 3017. [Abstract] [Full Text] [PDF]

				S. Choi, D. Sano, M. Cheung, M. Zhao, S. A. Jasser, A. J. Ryan, L. Mao, W.-T. Chen, A. K. El-Naggar, and J. N. Myers Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model Clin. Cancer Res., August 15, 2008; 14(16): 5081 - 5089. [Abstract] [Full Text] [PDF]